Overview

An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma

Status:
Unknown status

Trial end date:
2021-07-30

Target enrollment:

Participant gender:

Summary

The study is to evaluate the efficacy of BGB-A317 a in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL), as measured by Overall Response Rate (ORR) per the Lugano Classification

Phase:

Phase 2

Details

Lead Sponsor:

Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.